MAPT and Alzheimer disease: Changes in Aβ and tau were involved in a process of preclinical AD in a longitudinal study, and exacerbation of tauopathy during disease progression has been suggested to have a more direct effect on cognitive decline by neurodegeneration due to a damaged cytoskeleton1,45,46.